{"id":"https://openalex.org/W4405231069","doi":"https://doi.org/10.1093/bjd/ljae360.113","title":"P83 Baseline characteristics of the BeNeBio cohort: dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: a pragmatic, multicentre, randomized, controlled, non-inferiority study","display_name":"P83 Baseline characteristics of the BeNeBio cohort: dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: a pragmatic, multicentre, randomized, controlled, non-inferiority study","publication_year":2024,"publication_date":"2024-12-01","ids":{"openalex":"https://openalex.org/W4405231069","doi":"https://doi.org/10.1093/bjd/ljae360.113"},"language":"en","primary_location":{"id":"doi:10.1093/bjd/ljae360.113","doi":"https://doi.org/10.1093/bjd/ljae360.113","is_oa":true,"landing_page_url":"https://doi.org/10.1093/bjd/ljae360.113","pdf_url":"https://academic.oup.com/bjd/article-pdf/191/Supplement_3/ljae360.113/60941760/ljae360.113.pdf","source":{"id":"https://openalex.org/S45720283","display_name":"British Journal of Dermatology","issn_l":"0007-0963","issn":["0007-0963","1365-2133"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Dermatology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://academic.oup.com/bjd/article-pdf/191/Supplement_3/ljae360.113/60941760/ljae360.113.pdf","any_repository_has_fulltext":false},"authorships":[],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3918,"currency":"GBP","value_usd":5008},"apc_paid":{"value":3918,"currency":"GBP","value_usd":5008},"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"191","issue":"Supplement_3","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dose-reduction","display_name":"dose reduction","score":0.753000020980835},{"id":"https://openalex.org/keywords/il-17-inhibitors","display_name":"IL-17 inhibitors","score":0.9509999752044678},{"id":"https://openalex.org/keywords/il-23-inhibitors","display_name":"IL-23 inhibitors","score":1.0},{"id":"https://openalex.org/keywords/biologic-naive-patients","display_name":"biologic-naive patients","score":0.8270000219345093},{"id":"https://openalex.org/keywords/low-disease-activity","display_name":"low disease activity","score":0.7540000081062317},{"id":"https://openalex.org/keywords/non-inferiority","display_name":"non-inferiority","score":0.7929999828338623},{"id":"https://openalex.org/keywords/secukinumab","display_name":"secukinumab","score":0.7990000247955322},{"id":"https://openalex.org/keywords/ixekizumab","display_name":"ixekizumab","score":1.0},{"id":"https://openalex.org/keywords/brodalumab","display_name":"brodalumab","score":0.8709999918937683},{"id":"https://openalex.org/keywords/guselkumab","display_name":"guselkumab","score":0.9700000286102295},{"id":"https://openalex.org/keywords/risankizumab","display_name":"risankizumab","score":0.9869999885559082},{"id":"https://openalex.org/keywords/tildrakizumab","display_name":"tildrakizumab","score":0.9929999709129333},{"id":"https://openalex.org/keywords/bimekizumab","display_name":"bimekizumab","score":0.8069999814033508},{"id":"https://openalex.org/keywords/pasi","display_name":"PASI","score":0.8489999771118164},{"id":"https://openalex.org/keywords/dermatology-life-quality-index","display_name":"Dermatology Life Quality Index","score":0.8709999918937683},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.640999972820282},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.699999988079071}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9110021591186523},{"id":"https://openalex.org/C2777011040","wikidata":"https://www.wikidata.org/wiki/Q390643","display_name":"Psoriasis Area and Severity Index","level":3,"score":0.8408805131912231},{"id":"https://openalex.org/C2776173921","wikidata":"https://www.wikidata.org/wiki/Q25326609","display_name":"Dermatology Life Quality Index","level":3,"score":0.7382922172546387},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.6421704292297363},{"id":"https://openalex.org/C119060515","wikidata":"https://www.wikidata.org/wiki/Q1916617","display_name":"Interquartile range","level":2,"score":0.6377663016319275},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.55821293592453},{"id":"https://openalex.org/C2776260265","wikidata":"https://www.wikidata.org/wiki/Q511097","display_name":"Psoriatic arthritis","level":3,"score":0.5146483182907104},{"id":"https://openalex.org/C2779786854","wikidata":"https://www.wikidata.org/wiki/Q7444755","display_name":"Secukinumab","level":4,"score":0.5094006657600403},{"id":"https://openalex.org/C2779745271","wikidata":"https://www.wikidata.org/wiki/Q13574436","display_name":"Ixekizumab","level":5,"score":0.49974751472473145},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.46131253242492676},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.4487362504005432},{"id":"https://openalex.org/C3020604521","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Plaque psoriasis","level":3,"score":0.4420159161090851},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.34671279788017273}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1093/bjd/ljae360.113","doi":"https://doi.org/10.1093/bjd/ljae360.113","is_oa":true,"landing_page_url":"https://doi.org/10.1093/bjd/ljae360.113","pdf_url":"https://academic.oup.com/bjd/article-pdf/191/Supplement_3/ljae360.113/60941760/ljae360.113.pdf","source":{"id":"https://openalex.org/S45720283","display_name":"British Journal of Dermatology","issn_l":"0007-0963","issn":["0007-0963","1365-2133"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Dermatology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1093/bjd/ljae360.113","doi":"https://doi.org/10.1093/bjd/ljae360.113","is_oa":true,"landing_page_url":"https://doi.org/10.1093/bjd/ljae360.113","pdf_url":"https://academic.oup.com/bjd/article-pdf/191/Supplement_3/ljae360.113/60941760/ljae360.113.pdf","source":{"id":"https://openalex.org/S45720283","display_name":"British Journal of Dermatology","issn_l":"0007-0963","issn":["0007-0963","1365-2133"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Dermatology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/12","score":0.4699999988079071,"display_name":"Responsible consumption and production"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320321007","display_name":"ZonMw","ror":"https://ror.org/01yaj9a77"},{"id":"https://openalex.org/F4320321800","display_name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","ror":"https://ror.org/04jsz6e67"},{"id":"https://openalex.org/F4320336788","display_name":"Belgian Health Care Knowledge Centre","ror":"https://ror.org/02depad46"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4405231069.pdf","grobid_xml":"https://content.openalex.org/works/W4405231069.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3010318162","https://openalex.org/W2923455736","https://openalex.org/W4366819917","https://openalex.org/W3183768684","https://openalex.org/W4285010296","https://openalex.org/W2954778191","https://openalex.org/W3130836323","https://openalex.org/W3164716923","https://openalex.org/W4393219968","https://openalex.org/W2113944538"],"abstract_inverted_index":{"Abstract":[0],"Biologics":[1],"for":[2,77,118],"psoriasis":[3,47,70,200],"are":[4],"highly":[5],"effective":[6],"but":[7],"expensive.":[8],"Dose":[9],"reduction":[10],"(DR)":[11],"of":[12,27,41,61,66,104,113,124,130,252],"the":[13,28,231],"first-generation":[14],"biologics":[15,30],"has":[16],"proven":[17],"to":[18,55,96,100],"be":[19],"safe":[20],"and":[21,43,72,82,84,102,122,132,136,142,161,198,202,206,212,223,235,248],"(cost-)effective.":[22],"However,":[23],"data":[24],"on":[25],"DR":[26,40,97],"newest":[29],"is":[31,53],"scarce.":[32],"This":[33],"pragmatic":[34],"non-inferiority":[35],"study":[36],"evaluates":[37],"whether":[38],"controlled":[39],"IL-17":[42],"IL-23":[44],"inhibitors":[45,68],"in":[46,110],"patients":[48,125,144],"with":[49,69,126,244],"low":[50,221,240],"disease":[51,185],"activity":[52],"non-inferior":[54],"usual":[56],"care":[57],"(UC).":[58],"A":[59],"total":[60],"244":[62],"patients,":[63],"receiving":[64],"UC":[65],"IL-17/IL-23":[67],"area":[71,201],"severity":[73,203],"index":[74,173,204],"(PASI)":[75,205],"\u22645":[76,90],"at":[78,91,228],"least":[79],"6":[80],"months,":[81],"PASI":[83,131,222,234],"Dermatology":[85],"Life":[86],"Quality":[87],"Index":[88],"(DLQI)":[89],"inclusion,":[92],"were":[93,146,208],"randomized":[94],"2:1":[95],"(interval":[98],"prolongation":[99],"66":[101],"50%":[103],"UC)":[105],"or":[106],"UC.":[107],"Outcomes:":[108],"difference":[109],"cumulative":[111],"incidence":[112],"persistent":[114],"flares":[115],"(PASI":[116],">5":[117],"\u22653":[119],"months:":[120],"primary)":[121],"proportion":[123,251],"successful":[127],"DR,":[128],"course":[129],"DLQI,":[133],"safety,":[134],"costs,":[135],"pharmacokinetic":[137],"profile":[138],"(secondary).":[139],"Two":[140],"hundred":[141],"forty-four":[143],"(100%)":[145],"included:":[147],"14%":[148,179],"used":[149],"secukinumab,":[150],"25%":[151],"ixekizumab,":[152],"6%":[153],"brodalumab,":[154],"1%":[155],"bimekizumab,":[156],"30%":[157],"guselkumab,":[158],"21%":[159],"risankizumab":[160],"3%":[162],"tildrakizumab.":[163],"The":[164,215],"mean":[165,170,241],"age":[166],"was":[167,177,187,195,233],"51":[168],"years,":[169],"body":[171],"mass":[172],"(BMI)":[174],"27.5,":[175],"67%":[176],"male,":[178],"had":[180],"concomitant":[181],"psoriatic":[182],"arthritis,":[183],"median":[184,199,226],"duration":[186],"21":[188],"years":[189],"[interquartile":[190],"range":[191],"(IQR)":[192],"20],":[193],"47%":[194],"biologic":[196,246,253],"naive,":[197],"DLQI":[207,224,236],"0.0":[209],"(IQR":[210],"1.1":[211],"1.0,":[213],"respectively).":[214],"baseline":[216],"characteristics":[217],"highlight":[218],"a":[219,238,249],"very":[220],"(both":[225],"0)":[227],"inclusion":[229],"while":[230],"threshold":[232],"\u22645,":[237],"relatively":[239],"BMI":[242],"compared":[243],"general":[245],"cohorts,":[247],"well-balanced":[250],"naivety":[254],"vs.":[255],"non-naivety.":[256]},"counts_by_year":[],"updated_date":"2026-08-28T12:50:07.497085","created_date":"2025-10-10T00:00:00"}